Provided by Tiger Trade Technology Pte. Ltd.

Bright Minds Biosciences Inc

83.91
+6.017.72%
Post-market: 83.910.00000.00%17:01 EST
Volume:60.43K
Turnover:4.91M
Market Cap:816.63M
PE:-79.42
High:84.66
Open:77.60
Low:76.33
Close:77.90
52wk High:123.75
52wk Low:23.18
Shares:9.73M
Float Shares:5.24M
Volume Ratio:0.49
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0565
EPS(LYR):-1.2765
ROE:-26.98%
ROA:-15.72%
PB:12.47
PE(LYR):-65.73

Loading ...

Compelling Phase 2 Data and Prader–Willi Upside Support Buy Rating and Favorable Risk/Reward for DRUG

TIPRANKS
·
Yesterday

BTIG Sticks to Its Buy Rating for Bright Minds Biosciences (DRUG)

TIPRANKS
·
Feb 03

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

GlobeNewswire
·
Jan 10

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

GlobeNewswire
·
Jan 08

Crude Oil Down 2%; ISM Services PMI Surges In December

Benzinga
·
Jan 08

Press Release: Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

Dow Jones
·
Jan 07

New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday

Benzinga_recent_news
·
Jan 07

Bright Minds Biosciences Up Over 24%, on Track for Record High Close -- Data Talk

Dow Jones
·
Jan 07

Bright Minds Biosciences Says Phase 2 Trial Results of BMB-101 Show 'Robust' Reduction in Seizure

MT Newswires Live
·
Jan 06

U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure

Reuters
·
Jan 06

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Dec 18, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Dec 15, 2025

Press Release: Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)

Dow Jones
·
Nov 17, 2025

Bright Minds Biosciences to Present at Upcoming Conferences

GlobeNewswire
·
Oct 31, 2025

Bright Minds Biosciences Inc : Btig Initiates Coverage With Buy Rating; Target Price $72

THOMSON REUTERS
·
Sep 08, 2025

Bright Minds Biosciences Enters Deal for $100 Million At-The-Market Offering

MT Newswires Live
·
Sep 05, 2025

Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model

GlobeNewswire
·
Sep 04, 2025

Bright Minds Biosciences to Present at Upcoming Conferences

GlobeNewswire
·
Aug 25, 2025